Trevena (NASDAQ:TRVN) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued to investors on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

NASDAQ:TRVN opened at $1.99 on Friday. The company’s 50-day simple moving average is $3.77 and its 200-day simple moving average is $6.43. Trevena has a fifty-two week low of $1.13 and a fifty-two week high of $19.23. The stock has a market capitalization of $36.50 million, a P/E ratio of -0.74 and a beta of 1.02.

Trevena (NASDAQ:TRVN) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($9.25) by $9.02. The firm had revenue of $0.33 million during the quarter. On average, research analysts forecast that Trevena will post -32.25 EPS for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.